Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
|Videos|July 9, 2014
Developing a Mid-Size Specialty Pharmacy
Author(s)Davy James, Associate Editor
Michael Nameth, RPh, MBA, chief executive officer of Aureus Health Services, discusses the growth of his company as a mid-size specialty pharmacy.
Advertisement
Michael Nameth, RPh, MBA, chief executive officer of Aureus Health Services, discusses the growth of his company as a mid-size specialty pharmacy.
This video was shot at the Armada Health Care 2014 Specialty Pharmacy Summit and Expo in Las Vegas, Nevada.
Advertisement
Related to this article
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
2
Why Patients Fear Statins Will Affect Their Memory
3
Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4
4
Suzetrigine After Knee Replacement: Are Fewer Opioid Prescriptions Enough?
5